<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069640</url>
  </required_header>
  <id_info>
    <org_study_id>SUMS-21-73</org_study_id>
    <secondary_id>UMIN000003190</secondary_id>
    <nct_id>NCT01069640</nct_id>
  </id_info>
  <brief_title>Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiga University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shiga University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, immune response and
      clinical efficacies of HLA-A*0201 or HLA-A*0206 restricted epitope peptides URLC10 emulsified
      with Montanide ISA 51 for advanced non-small cell lung cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators previously identified three novel HLA-A*0201 or HLA-A*0206-restricted
      epitope peptides, which were derived from a cancer-testis antigen, URLC10, as targets for
      cancer vaccination against lung cancer. In this phase I trial, the investigators examine
      using a combination of these three peptides the safety, immunogenicity, and antitumor effect
      of vaccine treatment for HHLA-A*0201 or HLA-A*0206-positive advanced non-small cell lung
      cancer patients who failed to standard therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety (NCI CTCAE version3): the number of adverse events of vaccination therapy.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of tolerability (maximum tolerated dose, MTD and dose limiting toxicity, DLT) for the determination of the recommended dose for next phase trial.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological responses: Peptides specific CTL, Antigen cascade, Regulatory T cells, Cancer antigens and HLA levels.</measure>
    <time_frame>2 months (every time point(s) at which each course is completed)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical efficacy: Objective response rate (RECIST1.1), Tumor markers, Overall survival, Progression free survival.</measure>
    <time_frame>2 months (every time point(s) at which each course is completed)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>URLC10-1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URLC10-2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URLC10-3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides</intervention_name>
    <description>Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.</description>
    <arm_group_label>URLC10-1mg</arm_group_label>
    <arm_group_label>URLC10-2mg</arm_group_label>
    <arm_group_label>URLC10-3mg</arm_group_label>
    <other_name>URLC10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. NSCLC that can not undergo curative surgery and treatment, and is refractory to
             standard chemotherapy and radiotherapy

          2. ECOG performance status 0-2

          3. Age between 20 to 85

          4. Clinical efficacy can be evaluated by some methods

          5. No prior chemotherapy, radiation therapy, hyperthermia or immunotherapy within 4 weeks

          6. Life expectancy &gt; 3 months

          7. Laboratory values as follows 1500/mm3 &lt; WBC &lt; 15000/mm3 Platelet count &gt; 75000/mm3
             Asparate transaminase &lt; 3 X cutoff value Alanine transaminase &lt; 3 X cutoff value Total
             bilirubin &lt; 3 X cutoff value Serum creatinine &lt; 2X cutoff value

          8. HLA-A*0201 or HLA-A*0206

          9. Able and willing to give valid written informed consent

        Exclusion Criteria:

          1. Active and uncontrolled cardiac disease (i.e. coronary syndromes, arrhythmia)

          2. Myocardial infarction within six months before entry

          3. Breastfeeding and Pregnancy (woman of child bearing potential)

          4. Active and uncontrolled infectious disease

          5. Concurrent treatment with steroids or immunosuppressing agent

          6. Other malignancy requiring treatment

          7. Non-cured traumatic wound

          8. Decision of unsuitableness by principal investigator or physician-in-charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yataro Daigo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medical Oncology, Shiga University of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yataro Daigo, MD, PhD</last_name>
    <phone>81-77-548-2111</phone>
    <email>ydaigo@belle.shiga-med.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yataro Daigo, MD, PhD</last_name>
      <phone>81-77-548-2111</phone>
      <email>ydaigo@belle.shiga-med.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009 Aug;100(8):1502-9. doi: 10.1111/j.1349-7006.2009.01200.x. Epub 2009 May 14.</citation>
    <PMID>19459850</PMID>
  </reference>
  <reference>
    <citation>Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, Ikuta Y, Yokomine K, Imai K, Inoue M, Harada K, Mori T, Tsunoda T, Nakatsuru S, Daigo Y, Nomori H, Nakamura Y, Baba H, Nishimura Y. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer. 2008 Dec 1;123(11):2616-25. doi: 10.1002/ijc.23823.</citation>
    <PMID>18770861</PMID>
  </reference>
  <reference>
    <citation>Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci. 2008 Jul;99(7):1448-54. doi: 10.1111/j.1349-7006.2008.00844.x. Epub 2008 Apr 30.</citation>
    <PMID>18452554</PMID>
  </reference>
  <reference>
    <citation>Daigo Y, Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 2008 Feb;56(2):43-53. doi: 10.1007/s11748-007-0211-x. Epub 2008 Feb 24. Review.</citation>
    <PMID>18297458</PMID>
  </reference>
  <reference>
    <citation>Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 2007 Dec 15;67(24):11601-11.</citation>
    <PMID>18089789</PMID>
  </reference>
  <reference>
    <citation>Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov;98(11):1803-8.</citation>
    <PMID>17784873</PMID>
  </reference>
  <reference>
    <citation>Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, Ito T, Tsuchiya E, Kondo S, Nakamura Y. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res. 2006 Nov 1;66(21):10339-48.</citation>
    <PMID>17079454</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiga University</investigator_affiliation>
    <investigator_full_name>Yataro Daigo</investigator_full_name>
    <investigator_title>Professor, Director of Cancer Center</investigator_title>
  </responsible_party>
  <keyword>URLC10</keyword>
  <keyword>lung cancer</keyword>
  <keyword>vaccine</keyword>
  <keyword>HLA-A*0201</keyword>
  <keyword>HLA-A*0206</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

